Lesions situated in the nasopharynx
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Silver nitrate	75% AgNO3 25% KNO3	Topical (sticks)	Pain Skin irritation Septal perforation Methemoglobinemia (rare)	?	[20,21]
Xylometazoline	1:1000	Nasal spray	Rebound vasodilation (if prolonged use)	Closed-angle glaucoma	[24,25]
Tranexamic acid	500 mg/5 ml	Topical (gauze), for 10 min	?	?	[22,23]
Lesions situated in the oropharynx
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Tranexamic acid	500 mg/5 ml, 10 mL q.i.d.	Mouthwash suspension (swallow after use)	Nausea, vomiting and diarrhoea (25%) Colour vision disturbance	Dose reduction if GFR < 50 ml/mn Active thromboembolic disease	[[26], [27], [28], [29]]
Adrenaline	2.5–5 ml 1% in 5 ml 0.9% saline q.i.d.	Nebulisation	None	None	[30]
Inaccessible lesions (ENT)
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Tranexamic acid	1–1.5 g t.i.d.	Oral	Nausea, vomiting and diarrhoea (25%) Colour vision disturbance	Dose reduction if GFR < 50 ml/mn Active thromboembolic disease	[31]
	10–15 mg/kg t.i.d.	Intravenous
Pulmonary pathologies
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Tranexamic acid	500 mg/5 ml t.i.d. - q.i.d.	Nebulisation	None	?	[[43], [44], [45],60]
	1–1.5 g t.i.d.	Oral	Nausea, vomiting and diarrhoea (25%) Colour vision disturbance	Dose reduction if GFR < 50 ml/mn Active thromboembolic disease	[39]
	10 (−15) mg/kg t.i.d. - q.i.d.	Intravenous			[[40], [41], [42]]
Upper gastrointestinal bleeding
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Tranexamic acid	1–1.5 g t.i.d.	Oral	Nausea, vomiting and diarrhoea (25%) Colour vision disturbance	Dose reduction if GFR < 50 ml/mn Active thromboembolic disease	[47]
	10–15 mg/kg t.i.d.	Intravenous
Octreotide	100–200 mg t.i.d.	Subcutaneous	?	None	[50]
	10 mcg push then 25 mcg/h	Intravenous	If > 100 mcg/h: nausea, abdominal discomfort, diarrhoea
Rectal bleeding
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Tranexamic acid	500 mg, 10 ml water b.i.d.	Rectal (enema)	?	?	[53]
	1 g t.i.d.	Oral	Nausea, vomiting and diarrhoea (25%) Colour vision disturbance	Dose reduction if GFR < 50 ml/mn Active thromboembolic disease	[31]
Vesical bleeding
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Tranexamic acid	1 g t.i.d.	Oral	Nausea, vomiting and diarrhoea (25%) Colour vision disturbance	Dose reduction if GFR < 50 ml/mn Active thromboembolic disease	[60]
Tranexamic acid	100 ml of 5% b.i.d.	Intravesical	Intravesical clot retention	?	[60,68]
Prostate bleeding
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Tranexamic acid	1–1.5 g t.i.d.	Oral	Nausea, vomiting and diarrhoea (25%) Colour vision disturbance	Dose reduction if GFR < 50 ml/mn Active thromboembolic disease	[31]
Vaginal bleeding
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Tranexamic acid	500 mg/5 ml	Topical (gauze), apply pressure for 10 min	?	?	None
	1–1.5 g t.i.d.	Oral	Nausea, vomiting and diarrhoea (25%) Colour vision disturbance	Dose reduction if GFR < 50 ml/mn Active thromboembolic disease	None
Malignant ulcers
Therapy	Posology	Administration	Adverse effects	Contra-indications	Ref.
Alginate	–	Topical dressings	Mechanical damage upon dressing removal	?	[60,82]
Adrenaline	1:1000	Topical (gauze) for 5–10 min	Rebound bleeding Ischaemic necrosis	None	[60]
Tranexamic acid	500 mg in 5 ml	Topical (gauze)	?	?	[83,84]
	1 g b.i.d. for 1 week following cessation of bleeding	Oral	Nausea, vomiting and diarrhoea (25%) Colour vision disturbance	Dose reduction if GFR < 50 ml/mn Active thromboembolic disease	[83,84]

Remarks: “?” corresponds to information currently unavailable in existing literature.